The ways in which bacteria resist antibiotics

International Journal of Risk and Safety in Medicine

Volumn 17, Issue 3-4, 2005, Pages 111-116

  Andersson, Dan I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; PENICILLIN G; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL SURVIVAL; CATALYSIS; CATALYST; CLONING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SALIVA LEVEL; EVOLUTION; GENE AMPLIFICATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORIZONTAL GENE TRANSFER; HUMAN; INTEGRON; LETHALITY; NONHUMAN; PENICILLIN RESISTANCE; PLASMID; PNEUMONIA; POINT MUTATION; REVIEW; STOMACH ULCER; TRANSPOSON;

EID: 27744442637     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. D.I. Andersson and B.R. Levin, The biological cost of antibiotic resistance, Curr. Opin. Microbiol. 2 (1999), 489-493.
2. D.I. Andersson, Persistence of antibiotic resistant bacteria, Curr. Opin. Microbiol. 6 (2003), 452-456.
3. D.J. Austin, K.G. Kristinsson and R.M. Anderson, The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance, Proc. Natl. Acad. Sci. 96 (1999), 1152-1156.
4. R. Colgan and J.H. Powers, Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance, Am. Fam. Physician 64 (2001), 999-1004.
5. H.C. Davison, J.C. Low and M.E. Woolhouse, What is antibiotic resistance and how can we measure it?, Trends Microbiol. 8 (2000), 554-559.
6. V.I. Enne, D.M. Livermore, P. Stephens and L.M. Hall, Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction, Lancet 357 (2001), 1325-1328.
7. ISCAP Study group; S. Awasthi et al., Three day versus five day treatment with amoxicillin for non severe pneumonia in young children: a multicentre randomised controlled trial, BMJ, doi:10.1136/bmj.38049.490255.DE (published 30 March 2004).
8. M. Lipsitch, C.T. Bergstrom and B.R. Levin, The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions, Proc. Natl. Acad. Sci. 97 (2000), 1938-1943.
9. M. Lipsitch and B.R. Levin, The population dynamics of antimicrobial chemotherapy, Antimicrob. Agents Chemother. 41 (1997), 363-373.
10. D.M. Livermore, Bacterial resistance: origins, epidemiology, and impact, Infect. Dis. 36 (2003), S11-S23.
11. D.M. Livermore, Can better prescribing turn the tide of resistance?, Nat. Rev. Microbiol. 2 (2004), 73-78.
12. B.R. Levin, How can we predict the ecologic impact of an antimicrobial: the opinions of a population and evolutionary biologist, Clin. Microbiol. Infect. 7 (2001), 24-28.
13. B.R. Levin, Minimizing potential resistance: a population dynamics view, Clin. Infect. Dis. 33 (2001), S161-S169.
14. MASCOT study group, Hazir et al., Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial, Lancet 360 (2002), 835-841.
15. H. Seppala, T. Klaukka, J. Vuopio-Varkila, A. Muotiala, H. Helenius, K. Lager and P. Huovinen, The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance, N. Engl. J. Med. 337 (1997), 441-446.
16. M. Sjölund, K. Wreiber, D.I. Andersson, M.J. Blaser and L. Engstrand, Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori, Ann. Intern. Med. 139 (2003), 483-487.
17. A. Sullivan, C. Edlund and C.E. Nord, Effect of antimicrobial agents on the ecological balance of human microflora, Lancet Infect. Dis. 1 (2001), 101-104.